Skip to main content

Sensorineural Hearing Loss, Bilateral

2
Pipeline Programs
6
Companies
8
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Akouos
AkouosMA - Boston
2 programs
1
AAVAnc80-hOTOF via Akouos Delivery DevicePhase 1/2
Natural History StudyN/A
Prevail Therapeutics
2 programs
1
AAVAnc80-hOTOF via Akouos Delivery DevicePhase 1/21 trial
Natural History StudyN/A1 trial
Active Trials
NCT05572073Recruiting150Est. Feb 2029
NCT05821959Recruiting22Est. Oct 2028
Cochlear
CochlearAustralia - Macquarie Park
3 programs
Cochlear Nucleus CI532N/A1 trial
Commercially available cochlear implant and AI systemN/A1 trial
Factors Affecting Early Progress of Cochlear Implant Outcomes in AdultsN/A1 trial
Active Trials
NCT02755935Completed24Est. Sep 2017
NCT03304106Completed102Est. Sep 2019
NCT05265260Completed32Est. Sep 2022
Sensorion
SensorionFrance - Montpellier
2 programs
GenotypingN/A1 trial
Pure Tone Audiometry AssessmentN/A1 trial
Active Trials
NCT06354010Recruiting100Est. Jul 2027
NCT05402813Recruiting180Est. Nov 2028
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
Natural History StudyN/A
AAVAnc80-hOTOF via Akouos Delivery DevicePHASE_1_2
Oticon
OticonDenmark - Smørum
1 program
Neuro Cochlear Implant systemN/A1 trial
Active Trials
NCT05154188Not Yet Recruiting60Est. Feb 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Prevail TherapeuticsAAVAnc80-hOTOF via Akouos Delivery Device
OticonNeuro Cochlear Implant system
SensorionGenotyping
SensorionPure Tone Audiometry Assessment
Prevail TherapeuticsNatural History Study
CochlearFactors Affecting Early Progress of Cochlear Implant Outcomes in Adults
CochlearCommercially available cochlear implant and AI system
CochlearCochlear Nucleus CI532

Clinical Trials (8)

Total enrollment: 670 patients across 8 trials

NCT05821959Prevail TherapeuticsAAVAnc80-hOTOF via Akouos Delivery Device

Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss

Start: Sep 2023Est. completion: Oct 202822 patients
Phase 1/2Recruiting
NCT05154188OticonNeuro Cochlear Implant system

Post Approval Study to Assure the ContInued saFety and effectIveness of Neuro Cochlear Implant System in Adult Users

Start: Sep 2025Est. completion: Feb 202960 patients
N/ANot Yet Recruiting
NCT06354010SensorionGenotyping

Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis

Start: Jun 2024Est. completion: Jul 2027100 patients
N/ARecruiting
NCT05402813SensorionPure Tone Audiometry Assessment

Natural History in Children up to 16 Years With Mild to Profound Hearing Loss Due to Mutations in GJB2 / OTOF Genes

Start: Nov 2022Est. completion: Nov 2028180 patients
N/ARecruiting
NCT05572073Prevail TherapeuticsNatural History Study

Otoferlin Gene-mediated Hearing Loss Natural History Study

Start: Jul 2022Est. completion: Feb 2029150 patients
N/ARecruiting
NCT05265260CochlearFactors Affecting Early Progress of Cochlear Implant Outcomes in Adults

Factors Affecting Early Progress of Cochlear Implant Outcomes in Adults

Start: Apr 2022Est. completion: Sep 202232 patients
N/ACompleted
NCT03304106CochlearCommercially available cochlear implant and AI system

Clinical Investigation of New CI Delivery Models in an Adult Nucleus CI Population

Start: Oct 2017Est. completion: Sep 2019102 patients
N/ACompleted
NCT02755935CochlearCochlear Nucleus CI532

CI532 - Early Experience Study

Start: May 2016Est. completion: Sep 201724 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 actively recruiting trials targeting 670 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.